Abrilada Indications/Uses

Rheumatoid arthritis: Abrilada is indicated for reducing signs and symptoms, inducing major clinical response and clinical remission, inhibiting the progression of structural damage and improving physical function in adult patients with moderately to severely active rheumatoid arthritis.
Abrilada can be used alone or in combination with methotrexate or other disease modifying antirheumatic drugs (DMARDs).
Psoriatic arthritis: Abrilada is indicated for reducing the signs and symptoms of active arthritis in patients with psoriatic arthritis, inhibiting the progression of structural damage, and improving physical function in patients with psoriatic arthritis.
Abrilada can be used alone or in combination with disease modifying anti-rheumatic drugs.
Axial spondyloarthritis: Ankylosing spondylitis (AS): Abrilada is indicated for reducing signs and symptoms in patients with active ankylosing spondylitis.
Non-radiographic axial spondyloarthritis (Axial spondyloarthritis without radiographic evidence of AS): Abrilada is indicated for reducing signs and symptoms in patients with active non-radiographic axial spondyloarthritis (nr-axSpA) but with objective signs of inflammation by elevated C-Reactive Protein (CRP) and/or Magnetic Resonance Imaging (MRI), who have had an inadequate response to, or are intolerant to nonsteroidal anti-inflammatory drugs.
Plaque psoriasis: Abrilada is indicated for the treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy and when other systemic therapies are medically less appropriate.
Crohn's disease: Abrilada is indicated for the treatment of moderately to severely active Crohn's Disease in adult patients who have inadequate response to conventional therapy. Abrilada is also indicated for treatment in adult patients with moderately to severely active Crohn's Disease who have lost response to or are intolerant to infliximab.
Ulcerative colitis: Abrilada is indicated for treatment of moderately to severely active ulcerative colitis in adult patients who have had an inadequate response to conventional therapy including corticosteroids and 6-mercaptopurine (6-MP) or azathioprine (AZA), or who are intolerant to or have medical contraindications for such therapies.
Hidradenitis suppurativa (HS): Abrilada is indicated for the treatment of active moderate to severe hidradenitis suppurativa (acne inversa) in adult patients with an inadequate response to conventional systemic HS therapy.
Uveitis: Abrilada is indicated for the treatment of non-infectious intermediate, posterior and panuveitis in adult patients who have had an inadequate response to corticosteroids, in patients in need of corticosteroid-sparing, or in whom corticosteroid treatment is inappropriate.